BIOPHARMA
ByIs Nabla Bio Redefining AI-Driven Protein Engineering as Pharma Seeks Faster Paths to Biologics Innovation?
Executive Summary Nabla Bio is emerging as a next-generation AI biotech focused on computationally driven protein and antibody…
Is AbCellera Biologics Building a Durable AI Antibody Discovery Engine as Pharma Partnerships Signal Multi-Billion-Dollar Potential?
Executive Summary AbCellera Biologics has established itself as a global leader in AI-driven antibody discovery, combining advanced computational…
Is Recursion Pharmaceuticals Setting the Standard for AI-Powered Drug Discovery with Strategic Deals and a $20B+ Partnership Pipeline?
Executive Summary Recursion Pharmaceuticals has emerged as a leading clinical-stage TechBio company applying artificial intelligence, automation, and large-scale…
Can ReviR’s AI-Powered RNA Modulation Platform Convert $50M+ in Funding into Scalable Genetic Medicines?
Executive Summary ReviR Therapeutics continues to establish itself as a leader in RNA-targeting small molecule drug discovery, advancing…
Roche Reports Full-Year 2025 Results and Provides Strategic Portfolio Insights
Roche today announced its full-year 2025 performance and outlined its strategic positioning across key therapeutic areas. Roche maintained…
Top 10 Pharma Brands of 2025 — Sales Performance, Company Strategy & Market Outlook
The pharmaceutical market in 2025 was defined by high-value specialty brands delivering breakthrough outcomes in oncology, metabolic disease,…
